MedTrace Logo

An Observational Study of Current Practice Pattern on the Treatment of Women With Metastatic Breast Cancer Whose Tumors Overexpress Her2neu

NCT00153218 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 94

Last updated 2012-02-14

No results posted yet for this study

Summary

The purpose of this study is to observe clinical outcomes of metastatic breast cancer patients whose tumors overexpress the Her2neu protein and are being treated with trastuzumab (Herceptin)either alone or combination with chemotherapy or hormonal therapy.

Conditions

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Cancer Research Network

    lead OTHER

Principal Investigators

  • Elizabeth Tan-Chiu, MD · Cancer Reserach Network, Inc.

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00153218 on ClinicalTrials.gov